Lazard Asset Management
NAMS icon

Lazard Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Lazard Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,517
Closed -$732K – 2477
2024
Q4 		$732K Buy
+28,517
New +$606K ﹤0.01% 1256

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Lazard Asset Management's NAMS Position: Q1 2025 in Review

Lazard Asset Management sold out of NewAmsterdam Pharma (NAMS) in Q1 2025, closing a stake of 28,517 shares — an estimated $732K sold.

Lazard Asset Management first reported a position in NAMS in Q4 2024 and held it in 1 quarter. The position peaked at $732K in Q4 2024. 126 funds tracked by Wall St. Rank hold NAMS as of Q1 2025.

  • Lazard Asset Management reported no remaining NewAmsterdam Pharma position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 28,517 NewAmsterdam Pharma shares in Q1 2025, an estimated $732K.
  • Lazard Asset Management first reported a position in NewAmsterdam Pharma in Q4 2024 and held it in 1 quarter.
  • Lazard Asset Management's NewAmsterdam Pharma position peaked at $732K in Q4 2024.
  • 126 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.